Cardiovascular risks of corticosteroids;Risques cardiovasculaires d'une corticothérapie

Presse Medicale

Volumn 41, Issue 4, 2012, Pages 384-392

  Szwebel, Tali Anne ^a   Le Jeunne, Claire ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID RECEPTOR;

ATHEROMA; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DISEASE SURVEILLANCE; HEART PROTECTION; HYPERTENSION; MORBIDITY; MORTALITY; PROTEIN POLYMORPHISM; RISK ASSESSMENT; SHORT SURVEY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; PLAQUE, ATHEROSCLEROTIC; PULSE THERAPY, DRUG; RISK FACTORS;

EID: 84858745217     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.01.013     Document Type: Short Survey

References (70)

1. Roumestan C., Gougat C., Jaffuel D., Mathieu M. Glucocorticoids and their receptor: mechanisms of action and clinical implications. Rev Med Int 2004, 25:636-647.
2. Whitworth J.A., Mangos G.J., Kelly J.J. Cushing, cortisol and cardiovascular disease. Hypertension 2000, 36:912-916.
3. Andrews R.C., Walker B.R. Glucocorticoïds and insulin resistance: old hormones, new target. Clin Sci (Lond) 1999, 96:513-523.
4. Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoid by prescription in associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:767-770.
5. Ruyssen-Wiltrand A., Fautrel B., Saraux A., Le Loët X., Pham T. Risque cardiovasculaire associé à la corticothérapie à faible dose dans la polyarthrite rhumatoïde : revue de la littérature. Rev Rhum 2010, 77:542-549.
6. Brink M., Price S.R., Chrast J., Bailey J.L., Anwar A., Mitch W.E., et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001, 142(4):1489-1496.
7. Sayegh R., Auerbach S.D., Li X., Loftus R.W., Husted R.F., Stokes J.B., et al. Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5'-flanking region of the human epithelial sodium channel alpha subunit gene. J Biol Chem 1999, 274(18):12431-12437.
8. Lai K.N., Richards A.M., Nicholls M.G. Drug-induced hypertension. Adverse Drug React Toxicol Rev 1991, 10:31-46.
9. Clyburn E.B., Di Pette D.J. Hypertension induced by drugs and other substances. Semin Nephrol 1995, 15:72-86.
10. Whitworth J.A., Gordon D., Andrews J., Scoggins B.A. The hypertensive effect of synthetic glucorticoids in man: role of sodium and volume. J Hypertens 1989, 7:537-549.
11. Montrella-Waybill M., Clore J.N. Schoolwerth AC Watlington CO. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991, 72:1060-1066.
12. Williamson P.M., Kelly J.J., Whitworth J.A. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens 1996, 14:S37-S41.
13. Jackson S.H., Beevers D.G., Myers K. Does long-term low-dose corticosteroid therapy cause hypertension. Clin Sci (Lond) 1981, 61:381s-383s.
14. Shubin H. Long-term (5 or more years) administration of corticosteroids in pulmonary diseases. Dis Chest 1965, 48:287-290.
15. Thomas T.P. The complications of systemic corticosteroids therapy in the ederly. A retrospective study. Gerontology 1984, 30:60-65.
16. Walsh L.J., Wong C.A., Oborne J., Cooper S., Lewis S.A., Pringle M., et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001, 56:279-284.
17. Covar R.A., Leung D.Y., McCormick D., Steelman J., Zeitler P., Spahn J.D. Risk factors associated with glucocorticoid-induced adverse effects in chidren with severe asthma. J Allergy Clin Immunol 2000, 106:651-659.
18. Lucas C.E., Ledgerwood A.M. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984, 119:537-541.
19. Sprung C.L. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984, 311:1137-1143.
20. Pirpiris M., Yeung S., Dewar E., Jennings G.L., Whitworth J.A. Hydrocortisone-induced hypertension in men: the role of cardiac output. Am J Hypertens 1993, 6:287-294. [1993].
21. Whitworth J.A., Schyvens C.G., Zhang Y., Mangos G.J., Kelly J.J. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001, 28:993-996.
22. Sato A., Funder J.W., Okubo M., Kubota E., Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995, 8(8):823-828.
23. Fardet L., Kettaneh A., Gérol J., Toledano C., Tiev K.P., Cabane J. Short-term effect of dietary sodium intake on arterial blood pressure of patients treated with systemic corticosteroids: a prospective, randomised, crossover study. Rev Med Int 2009, 30:741-746.
24. Sacks F.M., Svetkey L.P., Vollmer W.M. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001, 344:3-10.
25. Gates P.E., Tanaka H., Hiatt W.R., Seals D.R. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004, 44:35-41.
26. Midgley J.P., Matthew A.G., Greenwood C.M., Logan A.G. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996, 275:1590-1597.
27. Graudal N.A., Galloe A.M., Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols and triglyceride: a meta-analysis. JAMA 1998, 279:1383-1391.
28. Kelly J.J., Mangos G., Williamson P.M., Whitworth J.A. Cortisol and hypertension. Clin Exp Pharmacol Physiol Suppl 1998, 25:S51-S56.
29. Grünfeld J.P., Eloy L., Ramos-Frendo B., Araujo A., Rothschild E., Russo-Marie F. Do glucocorticosteroids play a role in the regulation of blood pressure. A study performed with a glucocorticosteroid antagonist. Adv Nephrol Necker Hosp 1987, 16:53-68.
30. Fardet L., Flahault A., Kettaneh A., Tiev K.P., Généreau T., Tolédano C., et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007, 157(1):142-148.
31. Walsh L.J., Wong C.A., Oborne J., Cooper S., Lewis S.A., Pringle M., et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001, 56(4):279-284.
32. Fardet L., Cabane J., Kettaneh A., Lebbé C., Flahaut A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (oxford) 2007, 46:1102-1106.
33. Fardet L., Cabane J., Lebbé C., Morel P., Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol 2007, 57:604-609.
34. Fardet A., Flahault A., Kettaneh K.P., Tiev C., Tolédano C., Lebbe J., et al. Corticothérapie systémique et alimentation : suivi des recommandations diététiques et relation entre apports alimentaires et apparition d'une lipodystrophie. Revue Med Int 2007, 28:284-288.
35. Capron L. évolution des théories sur l'athérosclérose. Rev Prat 1996, 46:533-537.
36. Tedgui A. Pathogénèse de l'athérosclérose. Encycl med chir (éditions scientifiques et médicales elsevier SAS, Paris), neurologie, 17-046-A-20, 2001;7p.
37. Hanson.Inflammation atherosclerosis and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
38. Meyer O. Athérosclérose et connectivites. Rev Rhum 2001, 68:931-943.
39. Sarkissian T., Beyene J., Feldman B., McCrindle B., Silverman E.D. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 2007, 56:631-638.
40. Pacual J., Quereda C., Zamora J., Hernandez D. Steroids withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controllled trials. Transplantation 2004, 78:1548-1556. The spanish Group for Evidence-Based Medicine in Renal Transplantation.
41. Junge G., Neuhaus R., Schewior L., Klupp J., Guckelberger O., Langrehr J.M., et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005, 37:1695-1696.
42. Del Rincon I., O'Leary D.H., Haas R.W. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004, 50:3813-3822.
43. Paccalin M., Amoura Z., Godeau P., Becq-Giraudon B., Piette J.C. Ischemic events after initiation of steroid therapy in giant cell arteritis. Rev Med Interne 2000, 21:550-554.
44. Soubrier M., Dougados M. Atherosclerosis and rheumatoid arthritis. Rev Med 2006, 27:125-136.
45. Assous N., Touzé E., Meune C., Kahan A., Allanore Y. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based corhort study in France. Rev Rheum 2007, 74:72-78.
46. Warrington K.J., Kent P.D., Frye R.L., Lymp J.F., Kopecty S.L., Goronzy J.J., et al. Rheumatoid arthritis in an independent risk factor for multi-vessel coronary artery disease: a case-control study. Arthritis Res Ther 2005, 7:R984-R991.
47. Peters M.J., Vis M., van Halm V.P., Wolbink G.J., Voskuyl A.E., Lems W.F., et al. Changes in lipid profile during infliximab and corticosteroids treatment in rheumatoid arthritis. Ann Rheum Dis 2007, 66:958-961.
48. White D., Fayez Z., Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J 2006, 119:2125.
49. Bonnotte B., Huyen T.E., Chauffert B., Jouve J.L., Martin F., Lorcerie B. Bolus de corticoïdes : effets secondaires et précautions d'emploi. Presse Med 1997, 26:1070-1073.
50. Baethge B.A., Lidsky M.D., Goldberg J.W. A study of adverse effects oh high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Ann Pharmacother 1992, 26:316-320.
51. Renoux M., Hilliquin P., Menkès C.J. Les bolus de méthylprednisolone en rhumatologie. Ann Med Interne 1994, 145:133-139.
52. Greffiaud-Ricouard C. Hypertension artérielle secondaire d'origine toxique et médicamenteuse. Encyclopédie médico-chirurgicale-cardiologie-angiologie 1993, éditions Techniques, Paris, [11.301.G-10].
53. Chibane S., Feldman-Billard S., Rossignol I., Kassaei R., Mihoubi-Mantout F., Heron E. Short-term tolerance of three days pulse methylprednisolone therapy: a prospective study in 146 patients. Rev Med Interne 2005, 26:20-26.
54. Mukherjee A.P., Toh B.H., Chan G.L., Lau K.S., White J.C. Vascular complications in nephritic syndrome: relationship to steroid therapy and accelerated thromboplastin generation. Br Med J 1997, 4:273-276.
55. Isacson S. Effets of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol 1970, 7:212-216.
56. Conn D.L., Tmpkins R.B., Nichols W.L. Glucocorticoids in the management of vasculitis: a double edged sword. J Rheumatol 1988, 15:1181-1183.
57. Juchet H., Arlet P., Ollier S., Montane de la Roque P., LeTallec Y. Bolus de methylprednisolone et maladie de Horton/pseudopolyarthrite rhizomélique. Ann Med Interne 1992, 143:85-86.
58. Walters M.T., Cawley M.I.D. Combined suppressive drugtreatment in severe refractory rheumatoid disease: an analysis ofthe relative effects of parental methylprednisolone,cyclophosphamide. Ann Rheum Dis 1988, 47:924-929.
59. Halberg P. Survival and causes of death in patients withsystemic lupus erythematosus. Clin Rheumatol 1991, 10:367-368.
60. Cerisier A., Dacosta A., Brulport V., Deluc D., Rousset H., Isaac K. Severe coronary events and steroid bolus: an update with respect to three new cases. Arch Mal Cœur 1997, 90:1285-1288.
61. Bonnotte B., Huyen T.E., Chauffert B., Jouve J.L., Martin F., Lorcerie B. Bolus de corticoïdes : effets secondaires et précautions d'emploi. Presse Med 1997, 22:1070-1073.
62. Ueda N., Yoshikawa T., Chihara M. Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol 1988, 2:29-31.
63. Tvede N., Nielsen L.P., Andersen V. Bradycardia afterhigh-dose intravenous methylprednisolone therapy. Scand JRheumatol 1986, 15:305-309.
64. Christiansen C.F., Christensen S., Mehnert R., Cummings S.R., Chapurlat R.D., Sorensen H.T. Glucocorticoid use and risk of atrial fibrillation or flutter. A population-based, case-control study. Arch Intern Med 2009, 169:1677-1683.
65. Aslam A.K., Vasavada B.C., Sacchi T.J., Khan I.A. Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone. Am J Ther 2001, 8:303-305.
66. McLuckie A.E., Savage R.W. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 1993, 104:622-623.
67. Fisch C. Electrolytes and the heart. The heart 1986, McGraw-Hill, New York, p. 1466-1479.
68. White K.P., Driscol M.S., Rothe M.J., Grant-Kels J.M. Severe adverse cardiovascular effects of pulse steroid therapy: iscontinuous cardiac monitoring necessary. J Am Acad Dermatol 1994, 30:768-773.
69. Fardet L., Hanslik T., Blanchon T., Perdoncini-Roux A., Kettaneh A., Tiev K.P., et al. Long-term systemic corticosteroid therapy associated measures: description of the French internal medicine physicians' practices. Rev Med Int 2008, 29:975-980.
70. Gagliardi L. Le Jeunne C. Cortiothérapie et diabète. Presse Med 2012;41:. doi:10.1016/j.lpm.2012.01.008.